Virgin Australia Adjusts Fares Amid Rising Aviation Costs and Middle East Tensions 
Saudi Arabia Warns Oil Prices Could Surge Past $180 a Barrel Amid U.S.-Israel-Iran Conflict 
Trump Issues 48-Hour Ultimatum to Iran Over Strait of Hormuz, Threatens Power Grid Strikes 
Asian Currencies Rebound as Dollar Weakens, BOJ Holds Rates 
DOJ Antitrust Chief Rejects Political Fast-Track for Paramount-Skydance Deal 
Cyberattack on Stryker Triggers U.S. Government Warning Over Microsoft Intune Security 
Asian Markets Mixed as Oil Volatility and Inflation Fears Weigh on Sentiment 
Jeff Bezos Eyes $100 Billion Fund to Transform Manufacturing With AI 
Gold Prices Extend Losing Streak, On Track for Worst Weekly Loss Since 1983 
Super Micro Computer Shares Plunge After Co-Founder Charged in AI Chip Smuggling Case 
Xiaomi's AI Model "Hunter Alpha" Mistaken for DeepSeek's Next Release 
Asian Markets Tumble as BOJ Holds Rates, Oil Surges Past $110 
U.S.-Iran War Escalates: Marines Deploy, Strait of Hormuz Closure Drives Global Oil Crisis 
Goldman Sachs Delays Bank of England Rate Cut Forecast Amid Middle East Inflation Risks 
Federal Reserve Crisis: DOJ Standoff Threatens Powell's Succession and Rate Stability 
Amazon's "Transformer" Phone: Can It Succeed Where Fire Phone Failed? 
Qatar's Economy Under Pressure: How Regional Conflict Could Reshape Global Investment in 2026 
Samsung Group is currently negotiating to acquire Biogen Inc., the American biotech company headquartered in Cambridge, Massachusetts. If the talks turn out to be successful, it will be the South Korean manufacturing conglomerate's biggest transaction ever.
Samsung Group is really interested in the mega-deal proposal from Biogen Inc., and this is set to become its largest acquisition. In 2016, the company set a record for its largest transaction ever after buying Harman, an American electronics systems maker for vehicles, for $8 billion. Now, its possible acquisition of the biotech firm will top this amount by more than five times over.
According to The Korea Economic Daily, Biogen Inc. spoke to Samsung to offer some of its shares that could be worth over ₩50 trillion or about $42 billion, including the control premium. The biotech firm's market cap at the moment is moderately less than $35 billion.
An investment banking source revealed on Wednesday, Dec. 29, that Samsung Group may buy the US-based drugmaker that specializes in neurological diseases, including dementia and Alzheimer's. "Samsung is at the negotiating table with the sell-side to acquire Biogen," a senior official at a global investment bank told KED.
In case the stake acquisition turns out to be successful, Samsung will become one of the top-ranking global biotechnology companies. It will also be able to expand its pharmaceutical business and do more aside from biosimilar treatment drugs and manufacturing deals. As for Biogen, it is also expected to steadily make high operating profits once the deal is sealed.
"Samsung is nurturing bio business as a new growth engine," another insider stated. "Acquiring Biogen will create an opportunity to take a quantum leap."
If the acquisition talks failed, it was reported that Samsung would attempt to buy back the remaining stake owned by Biogen in Samsung Bioepis, their biosimilar joint venture. Meanwhile, the response to the acquisition news was good so far as Biogen's stock went up after the report was published.
Market Watch reported that Biogen's shares increased 8.9 percent in the afternoon trading on Wednesday, just after it was reported that Samsung Group is on the negotiation table with the US-based drugmaker to purchase stakes in the company that is valued at around $42 billion.
